Post-approval studies (Phase 4)Study completedNCT02948777
What this trial is testing
Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Who this might be right for
Type 2 Diabetes Mellitus
Marja-Riitta Taskinen 14